AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02407899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: For optimal control of patients' glucose, researchers can initiate insulin therapy at any time in this trial, choose any brands of insulin after discussion with the patient.
Study NCT02407899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: For optimal control of patients' glucose, researchers can initiate insulin therapy at any time in this trial, choose any brands of insulin after discussion with the patient.
Study NCT04851769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor plus statin
Description: Patients in the alirocumab arm will receive alirocumab 75 mg Q2W added to statin therapy (atorvastatin 20 mg/day or rosuvastatin 10mg/day).
Study NCT04851769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard statin therapy
Description: Patients will continue to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day.
Study NCT02407899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Take Metformin tablet 1.5g p.o. per day for 104 weeks (adjust the dose between 1-1.7g per day according to subject's specific situation) before or after randomization.
Study NCT02407899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Take Metformin tablet 1.5g p.o. per day for 104 weeks (adjust the dose between 1-1.7g per day according to subject's specific situation) before or after randomization.
Study NCT00525616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mabthera
Description: Two IV perfusions of 1000mg at 15 days intervals
Study NCT03044652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WO2085 Moisturising Cream
Description: 2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening. After improvement of the symptoms the frequency may be reduced by the patient as needed. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).
Study NCT03044652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estriol Cream 0.1%
Description: 0.5 g of the reference product Estriol Cream 0.1% will be applied intravaginally once daily in the evening for the first 3 weeks. Subsequently, the frequency will be reduced to twice a week for the last 3 weeks for all patients in this treatment group.
Study NCT02095145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02095145 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02095145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02095145 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02095145 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT02095145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomegranate-Extract Pill
Description: Given PO
Study NCT01019135 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Rehabilitation
Description: comparison of multiple cardiac rehabilitation program models
Study NCT01817491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: American Heart Association Diet
Study NCT01817491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reduced Fat Vegan Diet
Study NCT02134782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Yoga Intervention Group
Description: These children will not receive a study-supplied iPad. Use of child or hospital supplied iPad games, music, movies or books will be permitted without any modification, encouragement or discouragement of these activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
Study NCT02134782 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: iPad Activity Control Group
Description: These children will not receive yoga during the 3 week iPad activity period; instructors will receive specific training to ensure that no yoga occurs during this time frame. Use of child or hospital supplied iPad activities will be permitted instead of the study-supplied iPad activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
Study NCT00655213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Symphony D 2450
Study NCT00655213 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Symphony D 2450
Study NCT00655213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Symphony DR 2550
Study NCT00655213 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Symphony DR 2550
Study NCT01711788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrabone infusion of umbilical cord blood stem cells
Study NCT02124044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir and Daclatasvir
Description: Oral treatment with Asunaprevir 100mg (ASV), twice daily, and Daclatasvir 60mg (DCV), once daily, for 24 weeks in HIV/HCV genotype 1b patients
Study NCT02124044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir and Daclatasvir with BMS-791325
Description: Oral treatment with Asunaprevir 200mg (ASV), Daclatasvir 30 mg (DCV) and BMS-791325 75 mg in a fixed dose combination pill (FDC), twice daily, for 12 weeks in HIV/HCV genotype 1a or 1b patients
Study NCT02799537 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Randomized clinical study
Description: Participants will be randomly assigned to one of two advance directives and we will assess which they prefer. This is not a human health intervention
Study NCT02799537 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Randomized clinical study
Description: Participants will be randomly assigned to one of two advance directives and we will assess which they prefer. This is not a human health intervention
Study NCT01157624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxygen
Description: Subjects who are found to desaturate during treatment with air will be supplement with oxygen
Study NCT01157624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxygen
Description: Subjects who are found to desaturate during treatment with air will be supplement with oxygen
Study NCT02489357 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Undergo whole gland cryoablation
Study NCT02489357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given SC
Study NCT02489357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02489357 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04017364 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCB PTCA
Description: Predilatation of coronary de-novo stenosis followed by a PCB
Study NCT04017364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCB PTCA
Description: Predilatation of coronary de-novo stenosis followed by a SCB
Study NCT02430909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: * Pharmaceutical form: Solution for infusion~* Concentration: Vials at 80 mg/ml will be diluted with 0.9% sodium chloride to a final concentration to achieve the correct dose~* Route of administration: iv infustion
Study NCT02430909 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Certolizumab Pegol
Description: * Pharmaceutical form: Prefilled syringes~* Concentration: 200 mg/ml~* Route of administration: Subcutaneous injection
Study NCT02430909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Pharmaceutical form: Prefilled syringes~* Concentration: 200 mg/ml~* Route of administration: Subcutaneous injection
Study NCT02430909 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Certolizumab Pegol
Description: * Pharmaceutical form: Prefilled syringes~* Concentration: 200 mg/ml~* Route of administration: Subcutaneous injection
Study NCT02430909 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical form: Solution for infusion~* Concentration: 0.9% saline~* Route of administration: Intravenous infusion
Study NCT02232997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Hydration
Description: Sodium chloride hydration was set between 12 hours before coronary intervention (before contrast exposure during coronary angiography), continued during procedure, and 12 hours after procedure at 1 ml/kg/h (0.5 ml/kg/h For patients with congestive heart failure, New York Heart Association class>II, or LVEF \< 35%). For patients weighing more than 80 kg, bolus and infusion rates are limited to calculated values for patients weighing 80 kg
Study NCT02232997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simplified Hydration
Description: Hydration with sodium chloride was set 1 hour before procedure (before contrast exposure during coronary angiography), continued during procedure, and 4 hours after procedure at 3ml/kg/h (1.5ml/kg/h For patients with congestive heart failure, New York Heart Association class>II, or LVEF \<35%). For patients weighing more than 80 kg, bolus and infusion rates are limited to those calculated for patients weighing 80 kg.
Study NCT00552461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: IV, 1000 mg, two weeks, 2 times
Study NCT04851769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary imaging follow-up
Description: coronary angiography and OCT imaging at week 36 ± 2 weeks follow-up
Study NCT04851769 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary imaging follow-up
Description: coronary angiography and OCT imaging at week 36 ± 2 weeks follow-up
Study NCT01985152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Trimethylethanolamine
Study NCT01985152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02424136 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: 5 minute questionnaire focused on symptoms of allergic disease
Study NCT02424136 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Peanut Skin prick test
Description: Skin prick testing with peanut antigen, according to ASCIA Skin Prick testing manual
Study NCT02424136 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fraction of exhaled nitric oxide
Description: Measurement of exhaled nitric oxide, according to American Thoracic Society/ European Thoracic Society (ATS/ERS) standardised procedures (Not required for those age less than 6 years).
Study NCT02424136 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Spirometry
Description: Measurement of lung flows/volumes, according to ATS/ERS standardised procedures (Not required for those age less than 6 years).
Study NCT02424136 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Serum Peanut and Ara h2 specific immunoglobulin E
Description: Peanut and Ara h2 specific IgE antibodies
Study NCT02424136 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of blood biomarker
Description: Correlation of blood biomarker levels in patients with successful or unsuccessful peanut food challenge
Study NCT02424136 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Peanut food challenge
Description: Open label peanut challenge conducted according to ASCIA's peanut challenge protocol and PRACTALL consensus report
Study NCT01784900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catumaxomab 100µg
Study NCT01784900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catumaxomab 140µg
Study NCT02795182 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Zanubrutinib
Study NCT02795182 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tislelizumab
Study NCT03097666 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: C2 CRYOBALLOON SWIPE ABLATION SYSTEM
Description: The C2 CryoBalloon Swipe Ablation System (CryoBalloon Swipe) is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal diagnostic endoscopes.
Study NCT04194086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: posaconazole oral suspensions
Description: posaconazole oral suspensions（5mg/kg/d,tid) will be administered specially febrile neutropenia patients four times a day and blood samples will be taken any hours after the first dose at least Day 7.
Study NCT00286234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3 acid ethyl esters
Description: 4 q qd
Study NCT00286234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended release niacin
Description: 2 g qpm
Study NCT00286234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: omacor placebo plus niaspan placebo
Study NCT00286234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3 acid ethyl esters
Description: 4 g qd
Study NCT00286234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combined treatment
Description: omega-3 acid ethyl esters 4 g qd and extended release niacin, titrate up to 2 g Qpm
Study NCT02510885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AngioVue SD-OCT
Description: OCT-A allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. SD-OCT units use the light source used in commercially available and FDA-cleared OCT units on a modified platform. Optovue, Inc. has developed a customized SD-OCT system that implements a novel algorithm, the amplitude-based method of split-spectrum amplitude-decorrelation angiography (SSADA) for OCT-A. This detects motion in the blood vessel lumen by measuring the variation in reflected OCT signal amplitude between consecutive cross-sectional scans. Optovue has integrated the novel SSADA algorithm into their commercially approved RTVue SD-OCT unit for their OCT-A unit, the AngioVue. This unit is being conducted under an abbreviated IDE.
Study NCT02699047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Encapsuled fish oil
Description: Fish oil extracted from sardine, mackerel and anchovy. Nutritional information per capsule: Kcal: 13; protein: 0.35g; Total Fats: 1.25g; Saturated fat: 0g; polyunsaturated fat: 0.75g; EPA: 0.5g; DHA: 0.25g; Cholesterol: 0g. The supplement was provided in gelatinous capsule with antioxidant (tocopherols).
Study NCT02699047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Encapsulated Olive oil
Description: Extra virgin olive oil. Nutritional information per capsule: Kcal: 10; protein: 0.35g; Total Fats: 1g; Saturated fat: 0.1 g; monounsaturated fat: 0.75g; polyunsaturated fat: 0.1g; EPA: 0g; DHA: 0g; oleic acid: 0.65g; Cholesterol: 0g. The supplement was provided in gelatinous capsule without antioxidants.
Study NCT05179330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OMEGO®
Description: Lower limb rehabilitation with and without visual feedback
Study NCT01773057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NHGDoc domain Heart Failure
Description: Healthcare providers receive patient specific alerts in terms of diagnosing and treatment of patients with heart failure
Study NCT03098667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA Protector
Description: After induction of general anesthesia, the LMA Protector will be applied for airway management. The size of the laryngeal mask will be chosen according to the manufacturer's instructions. Lubricant gel will be applied to the dorsal side of the mask to ease the insertion to the oropharynx. The cuff of the mask will be filled with air by syringe until the indication of the integrated cuff pressure indicator is appropriate according to the manufacturer (green indication). If the indication changes during surgery, air will be added or removed accordingly. If the ventilation of the patient is inadequate at the beginning or anytime during the operation, the mask will be removed and the patient will be intubated.
Study NCT03098667 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube
Description: After induction of general anesthesia, the endotracheal tube be applied for airway management. The size of the tube will be 7.5 for female and 8.5 for male patients. The cuff of of the tube will be filled with 10ml air.
Study NCT01214070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vision Restoration Therapy
Description: Therapy that enhances the neuronal plasticity of the visual system
Study NCT01214070 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NVT Eye Scanning Therapy
Description: Therapy that trains eye and head scanning into the blind hemianoptic visual field
Study NCT02586155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apabetalone
Description: 100 mg capsule
Study NCT01214070 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric Viewing Training
Description: Therapy that trains the person to compensate for visual field loss by learning to move the visual field loss to the position that is least likely to impact the current visual task
Study NCT01214070 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: Therapy that encourages subjects to do daily visual tasks at home while having no training or intended intervention benefit
Study NCT03746015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV subcutaneous injection comprised of 1 molecularly characterized, attenuated dengue virus strain, and 3 chimeric dengue virus strains with potencies of not less than 3.3, 2.7, 4.0, and 4.5 log10 plaque forming units (PFU) per dose of TDV-1, TDV-2, TDV-3, and TDV-4, respectively.
Study NCT02889900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib and olaparib
Description: Cediranib tablets oral dose 30 mg once daily; Olaparib(Lynparza) tablet 200 mg twice daily~Dose reduction for both products is allowed
Study NCT02625025 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low pression pneumoperitoneum
Description: Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.~Intra-abdominal pressure will be maintained at 8 mm Hg during pneumoperitoneum creation and insertion of trocars.
Study NCT02625025 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Pression Pneumoperitoneum
Description: Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.~Intra-abdominal pressure will be maintained at 12 mm Hg during pneumoperitoneum creation and insertion of trocars.
Study NCT02625025 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Port Access Laparoscopy
Description: Laparoscopy surgery with use of only one incision of 2 cm in the umbilicus in order to threat benign adnexal pathology
Study NCT01729767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: Patients who were randomly allocated to the Acyclovir group besides sticking with low salt diet will take the Acyclovir 400 mg pills for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a day for the last 10 days. Patients would receive the medication in 2 sessions, first in the beginning of the study and the rest after 10 days. This way it would boost their compliance, and physicians would be aware of possible complications. Patients will report changes in their symptoms 10 days after initiating the drug and in 1, 3, and 6 month intervals. All changes in frequency and duration of vertigo attacks are recorded, and their tinnitus and aural fullness is recorded in a 0(with no symptom) to 4 (very severe) scale.
Study NCT01729767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants who are randomly placed in placebo group, besides sticking with low salt diet will take the placebo (inert ingredient) for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a day for the last 10 days. Patients would receive the medication in 2 sessions, first in the beginning of the study and the rest after 10 days. This way it would boost their compliance, and physicians would be aware of possible complications. Patients will report changes in their symptoms 10 days after initiating the drug and in 1, 3, and 6 month intervals. All changes in frequency and duration of vertigo attacks are recorded, and tinnitus and aural fullness is recorded in a 0(with no symptom) to 4 (very severe) scale.
Study NCT02586155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsule manufactured to mimic RVX000222 100 mg capsule
Study NCT02586155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: High-Intensity Statin
Study NCT01821599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nonaccelerated Rehabilitation
Description: Nonaccelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction in 6 months of recovery.
Study NCT01821599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated Rehabilitation
Description: Accelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction in 4 months of recovery.